Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Checking of Remaining Drugs Would Save 9.7 Billion Yen Annually: Estimate by Health and Labor Science Research Group
November 1, 2013
- New CSIMC Healthcare Rep Nakagawa Says Against Perpetuation of Premium
October 31, 2013
- MHLW Investigating Whether Advertising for Diovan Violates PAL
October 31, 2013
- Generic Use for Anti-Allergic Agents Jumps after Pilot Leaflet Project: Kyokai Kenpo
October 30, 2013
- Causal Relationship between Tamiflu and Abnormal Behavior Not Identified: PAFSC Subcommittee
October 30, 2013
- Health Ministry Subcommittees Agree to Continue Suspending Recommendation for HPV Vaccines
October 30, 2013
- MHLW Discussing OTC Status for Certain In Vitro Diagnostics
October 30, 2013
- 1st Committee Backs Japan Tobacco’s Hyperphosphatemia Treatment
October 30, 2013
- MHLW Rejects 2 Applicants for Cell-Based Flu Vaccine Subsidy Project
October 29, 2013
- Conclusion of TPP Talks over IP Rights Postponed
October 29, 2013
- Kenporen Calls for Taking 6 APIs Over the Counter
October 29, 2013
- LDP Establishes Study Group on Pharmaceutical Industry Policy; 11 Domestic Drug Makers to Participate
October 28, 2013
- TPP IP Talks Kick Off in Tokyo, Government Task Force to Hold Press Conference on Oct 28
October 25, 2013
- Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
- Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
- Lawmakers Concerned over Effects of Diovan Papers on Public Finances for Health Insurance
October 24, 2013
- Probable Price Settlement Rate of Lower 70% Range “Disappointing”: MHLW’s Economic Affairs Head Jo
October 24, 2013
- PFSB Notification Calls for Revisions to Precautions Sections of Package Inserts for Olmesartan and Other Drugs
October 24, 2013
- MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
- Govt Task Force Briefs Trade Groups on Tokyo’s Hosting of TPP Interim Talks on IP
October 23, 2013
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…